Johnson & Johnson (JNJ) Stock Analysis

Market Cap	248.84 B	P/E(ttm)	24.10
Enterprise Value	243.06 B	P/B	3.81

Financial Strength : 6/10

		vs industry	vs history
Cash to Debt	1.305	JNJ's Cash to Debt is ranked lower than 61% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 6.36 vs. JNJ: 1.305 )	JNJ' s 10-Year Cash to Debt Range Min: 0.62 Max: 6.01 Current: 1.31 0.62 6.01
Equity to Asset	0.112	JNJ's Equity to Asset is ranked lower than 87% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.52 vs. JNJ: 0.112 )	JNJ' s 10-Year Equity to Asset Range Min: 0.11 Max: 0.44 Current: 0.11 0.11 0.44
Interest Coverage	33.9	JNJ's Interest Coverage is ranked lower than 71% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 10000.00 vs. JNJ: 33.9 )	JNJ' s 10-Year Interest Coverage Range Min: 34 Max: No Debt Current: 33.9

F-Score: 5
Z-Score: 4.85
M-Score: -2.51

Profitability & Growth : 7/10

		vs industry	vs history
Operating margin (%)	23.60	JNJ's Operating margin (%) is ranked higher than 84% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 8.70 vs. JNJ: 23.60 )	JNJ' s 10-Year Operating margin (%) Range Min: 21.6 Max: 27.1 Current: 23.6 21.6 27.1
Net-margin (%)	16.1	JNJ's Net-margin (%) is ranked higher than 84% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 6.20 vs. JNJ: 16.1 )	JNJ' s 10-Year Net-margin (%) Range Min: 14.9 Max: 21.7 Current: 16.1 14.9 21.7
ROE (%)	16.7	JNJ's ROE (%) is ranked higher than 89% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 7.20 vs. JNJ: 16.7 )	JNJ' s 10-Year ROE (%) Range Min: 16.7 Max: 30.5 Current: 16.7 16.7 30.5
ROA (%)	8.9	JNJ's ROA (%) is ranked higher than 86% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 4.00 vs. JNJ: 8.9 )	JNJ' s 10-Year ROA (%) Range Min: 8.5 Max: 17.9 Current: 8.9 8.5 17.9
ROC (Joel Greenblatt) (%)	73.70	JNJ's ROC (Joel Greenblatt) (%) is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 14.40 vs. JNJ: 73.70 )	JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range Min: 57 Max: 114.4 Current: 73.7 57 114.4
Revenue Growth (%)	1.9	JNJ's Revenue Growth (%) is ranked higher than 80% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 6.20 vs. JNJ: 1.9 )	JNJ' s 10-Year Revenue Growth (%) Range Min: 1 Max: 10.2 Current: 1.9 1 10.2
EBITDA Growth (%)	1.4	JNJ's EBITDA Growth (%) is ranked higher than 86% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 4.35 vs. JNJ: 1.4 )	JNJ' s 10-Year EBITDA Growth (%) Range Min: 1.2 Max: 13.2 Current: 1.4 1.2 13.2
EPS Growth (%)	-3.2	JNJ's EPS Growth (%) is ranked higher than 68% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 8.20 vs. JNJ: -3.2 )	JNJ' s 10-Year EPS Growth (%) Range Min: -6.5 Max: 12.5 Current: -3.2 -6.5 12.5

» JNJ's 10-Y Financials

Financials

Revenue & Net Income

Cash & Debt

Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

Q3 2012

Q4 2012

Q1 2013

» Details

Insider Trades

Latest Guru Trades with JNJ

Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus

Guru	Date	Trades	Impact to Portfolio	Price Range * (?)	Current Price	Change from Average	Current Shares
John Hussman	2013-03-31	Reduce -99.47%	0.93%	$70.1 - $81.53	$ 88.46	17%	2650
Yacktman Focused Fund	2013-03-31	Add 22.58%	0.78%	$70.1 - $81.53	$ 88.46	17%	3800000
Donald Yacktman	2013-03-31	Add 16.02%	0.57%	$70.1 - $81.53	$ 88.46	17%	9740875
Yacktman Fund	2013-03-31	Add 15.71%	0.53%	$70.1 - $81.53	$ 88.46	17%	4050000
Ray Dalio	2013-03-31	Reduce -55.3%	0.07%	$70.1 - $81.53	$ 88.46	17%	76293
Joel Greenblatt	2013-03-31	Reduce -58.46%	0.05%	$70.1 - $81.53	$ 88.46	17%	8669
John Hussman	2012-12-31	Reduce -59.89%	1.26%	$67.97 - $72.52	$ 88.46	26%	501750
Joel Greenblatt	2012-12-31	New Buy	0.09%	$67.97 - $72.52	$ 88.46	26%	20867
Ray Dalio	2012-12-31	Reduce -36.71%	0.09%	$67.97 - $72.52	$ 88.46	26%	170693
Warren Buffett	2012-12-31	Reduce -33.52%	0.02%	$67.97 - $72.52	$ 88.46	26%	327100
George Soros	2012-09-30	Add 1557.29%	2.73%	$67.21 - $69.55	$ 88.46	29%	2568800
Warren Buffett	2012-09-30	Reduce -95.24%	0.9%	$67.21 - $69.55	$ 88.46	29%	492028
John Hussman	2012-09-30	Reduce -28.56%	0.63%	$67.21 - $69.55	$ 88.46	29%	1251000
Donald Yacktman	2012-09-30	Add 3.65%	0.12%	$67.21 - $69.55	$ 88.46	29%	8387771
Joel Greenblatt	2012-09-30	Sold Out	0.04%	$67.21 - $69.55	$ 88.46	29%	0
Tweedy Browne	2012-06-30	Add 18.1%	1.61%	$61.94 - $67.65	$ 88.46	38%	4398798
Warren Buffett	2012-06-30	Reduce -64.39%	1.61%	$61.94 - $67.65	$ 88.46	38%	10333128
Donald Yacktman	2012-06-30	Add 7.77%	0.26%	$61.94 - $67.65	$ 88.46	38%	8092590
George Soros	2012-06-30	New Buy	0.15%	$61.94 - $67.65	$ 88.46	38%	155000
Ray Dalio	2012-06-30	Add 48.49%	0.11%	$61.94 - $67.65	$ 88.46	38%	329793
PRIMECAP Management	2012-06-30	Add 7.21%	0.11%	$61.94 - $67.65	$ 88.46	38%	14494287
Joel Greenblatt	2012-06-30	Reduce -28.8%	0.02%	$61.94 - $67.65	$ 88.46	38%	7777

More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Johnson & Johnson

George Soros Keeps Buying

March 15, 2013

With a net worth of $19.2 billion, legendary investor Guru George Soros, founder of the best-performing hedge fund of all time, now manages his personal and family fortune as well as multibillion-dollar philanthropic endowments under the Soros Fund Management. Selling over half of his gold holdings at the end of 2012, the 82-year-old trader-philanthropist has a portfolio valued at $8.36 billion at the end of the fourth quarter, with 179 stocks, of which 61 are new additions. According to GuruFocus, the stocks on Soros’ keeps-buying list are Johnson & Johnson (JNJ), Delta Air Lines Inc. (DAL) and technology patent portfolio manager Acacia Research Corporation (ACTG), among others. Read more...

Sectors to Monitor While the Nation Hangs from the Fiscal Cliff

December 31, 2012

It’s the last day of the year and solutions pertaining to the fiscal cliff disagreement remain far and unseen. What we are seeing, however, is the continuous outpouring of commentators and pundits reflecting on the entire debacle, inflating into one big ongoing extravaganza. Read more...

Prem Watsa’s RFP Stake Gets Bigger

December 19, 2012

After adding 4.84 percent to his stake of paper and wood products company Resolute Forest Products (RFP), Fairfax Financial Holdings’ Prem Watsa now has a total holding of 19.9 million shares. The stake increase was reported yesterday by GuruFocus Real Time Picks. Read more...

“$2-Billion Man” Prem Watsa Revisited, Plus His Profit-Generating Stocks This Year

December 18, 2012

For a man who once said, “You have to turn your back sometimes,” pertaining to his tendency to go against the grain and delve in out-of-favor bets, one cannot help but be lured into the fascinating investment moves of Canadian investor, Prem Watsa. Read more...

Billionaire Investor George Soros’ Q3 Portfolio Updates: Big Increases in JNJ and CF

November 15, 2012

Labeled as “one of history’s most successful financiers,” legendary Guru George Soros has updated his Soros Fund Management LLC hedge fund portfolio with a total of 167 transactions: Read more...

Prem Watsa’s Temporary Hedging Losses Could Lead to Outsized Gains Again

October 30, 2012

Prem Watsa’s investing prowess with the float of his Canadian insurance company Fairfax Financial often draws comparisons to Warren Buffett, but the firm reported losses in its portfolio for the third quarter. While stocks delivered positive returns, even with the derelict Research In Motion (RIMM) in the portfolio, early hedges ultimately outweighed gains. The last time Watsa was early on hedging, he made billions. Read more...

GuruFocus.com Interview with Steve Romick, Portfolio Manager of FPA Crescent

October 9, 2012

GuruFocus readers recently got to ask Steve Romick, FPA Crescent portfolio manager, their questions about investing. Romick's mutual fund FPA Crescent Fund is up 19.76% over the last year and has delivered an annualized return exceeding 9% over the last decade. His fund is slightly different from most mutual funds in that it is diversified across a different basket of asset classes to provide equity rates of return with less risk. Read more...

52-Week Highs: FIS, JNJ, HCP, HSY, FE,

July 9, 2012

These are guru stocks that reached 52-week high in the past week: Read more...

Ray Dalio and Warren Buffett Both Own These Three Stocks

June 6, 2012

Ray Dalio and Warren Buffett are both at the top of their profession: Dalio’s Bridgewater Associates usurped the title of best-performing money management firm in history from George Soros in recent years. Warren Buffett of Berkshire Hathaway is the preeminent investor of the century with a long track record of above-average returns. Read more...

Stocks Warren Buffett and Prem Watsa Have in Common in 2012

May 31, 2012

Investors Warren Buffett and Prem Watsa have a lot in common. Both run insurance companies and invest the “float” – the money from insurance premiums that has not been used for disasters. Both are unusually successful at it. Prem Watsa has an 8,396 percent 25-year cumulative return compared to 829.8% for the S&P, and Warren Buffett has a 4,724% percent 25-year cumulative return. Read more...

» More Articles for JNJ

		vs industry	vs history
P/E(ttm)	24.10	JNJ's P/E(ttm) is ranked higher than 73% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 29.76 vs. JNJ: 24.10 )	JNJ' s 10-Year P/E(ttm) Range Min: 10.5 Max: 34.05 Current: 24.1 10.5 34.05
P/B	3.80	JNJ's P/B is ranked lower than 53% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 3.00 vs. JNJ: 3.80 )	JNJ' s 10-Year P/B Range Min: 2.71 Max: 8.59 Current: 3.8 2.71 8.59
P/S	3.70	JNJ's P/S is ranked lower than 60% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.32 vs. JNJ: 3.70 )	JNJ' s 10-Year P/S Range Min: 2.16 Max: 5.99 Current: 3.7 2.16 5.99
PFCF	21.00	JNJ's PFCF is ranked higher than 75% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 25.89 vs. JNJ: 21.00 )	JNJ' s 10-Year PFCF Range Min: 10.29 Max: 31.92 Current: 21 10.29 31.92
EV-to-EBIT	15.2	JNJ's EV-to-EBIT is ranked higher than 74% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 21.70 vs. JNJ: 15.2 )	JNJ' s 10-Year EV-to-EBIT Range Min: 8.4 Max: 24.7 Current: 15.2 8.4 24.7
PEG	15.9	JNJ's PEG is ranked lower than 63% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.23 vs. JNJ: 15.9 )	JNJ' s 10-Year PEG Range Min: 1.13 Max: 45.69 Current: 15.9 1.13 45.69
Shiller P/E	19.9	JNJ's Shiller P/E is ranked higher than 87% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 30.12 vs. JNJ: 19.9 )	JNJ' s 10-Year Shiller P/E Range Min: 12.9 Max: 30.41 Current: 19.9 12.9 30.41

		vs industry	vs history
Dividend Yield	2.70	JNJ's Dividend Yield is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.36 vs. JNJ: 2.70 )	JNJ' s 10-Year Dividend Yield Range Min: 1.1 Max: 3.84 Current: 2.7 1.1 3.84
Dividend Payout	0.6623	JNJ's Dividend Payout is ranked higher than 86% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.86 vs. JNJ: 0.6623 )	JNJ' s 10-Year Dividend Payout Range Min: 0.37 Max: 0.65 Current: 0.66 0.37 0.65
Dividend growth (3y)	5.6	JNJ's Dividend growth (3y) is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: -0.95 vs. JNJ: 5.6 )	JNJ' s 10-Year Dividend growth (3y) Range Min: 5.6 Max: 12.5 Current: 5.6 5.6 12.5
Yield on cost (5-Year)	3.89	JNJ's Yield on cost (5-Year) is ranked higher than 96% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.42 vs. JNJ: 3.89 )	JNJ' s 10-Year Yield on cost (5-Year) Range Min: 1.59 Max: 5.54 Current: 3.89 1.59 5.54
Share Buyback Rate	-0.2	JNJ's Share Buyback Rate is ranked higher than 93% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: -2.00 vs. JNJ: -0.2 )	JNJ' s 10-Year Share Buyback Rate Range Min: 1.5 Max: -1.9 Current: -0.2

		vs industry	vs history
Price/Net Current Asset Value	20.2	JNJ's Price/Net Current Asset Value is ranked higher than 83% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 10.20 vs. JNJ: 20.2 )	JNJ' s 10-Year Price/Net Current Asset Value Range Min: 16.2 Max: 36.7 Current: 20.2 16.2 36.7
Price/Tangible Book	18.1	JNJ's Price/Tangible Book is ranked higher than 96% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 3.40 vs. JNJ: 18.1 )	JNJ' s 10-Year Price/Tangible Book Range Min: 7 Max: 18.4 Current: 18.1 7 18.4
Price/DCF (Projected)	1.5	JNJ's Price/DCF (Projected) is ranked higher than 77% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.60 vs. JNJ: 1.5 )	JNJ' s 10-Year Price/DCF (Projected) Range Min: 1 Max: 2.1 Current: 1.5 1 2.1
Price/Median PS Value	1	JNJ's Price/Median PS Value is ranked higher than 82% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.70 vs. JNJ: 1 )	JNJ' s 10-Year Price/Median PS Value Range Min: 0.8 Max: 1.6 Current: 1 0.8 1.6
Price/Graham Number	4.4	JNJ's Price/Graham Number is ranked higher than 89% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.30 vs. JNJ: 4.4 )	JNJ' s 10-Year Price/Graham Number Range Min: 2 Max: 4.2 Current: 4.4 2 4.2
Earnings Yield (Greenblatt)	6.60	JNJ's Earnings Yield (Greenblatt) is ranked higher than 80% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.90 vs. JNJ: 6.60 )	JNJ' s 10-Year Earnings Yield (Greenblatt) Range Min: 4.1 Max: 11.9 Current: 6.6 4.1 11.9
Forward Rate of Return (Yacktman)	5.8	JNJ's Forward Rate of Return (Yacktman) is ranked higher than 70% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 9.82 vs. JNJ: 5.8 )	JNJ' s 10-Year Forward Rate of Return (Yacktman) Range Min: 3.1 Max: 19.2 Current: 5.8 3.1 19.2

Industry:	Drug Manufacturers - Major
Compare:	GSK, PFE, RHHBY, NVS, ABT
Traded in other countries:	JNJ.Germany

	Worst	Neutral			Best
Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

Financial Strength : 6/10

Profitability & Growth : 7/10

Financials

Guru Trades

JNJ Guru Trades in Q2 2012

JNJ Guru Trades in Q3 2012

JNJ Guru Trades in Q4 2012

JNJ Guru Trades in Q1 2013

Insider Trades

Latest Guru Trades with JNJ

Top Ranked Articles about Johnson & Johnson

Ratios

Dividend & Buy Back

Valuation & Return

Business Description

Headlines

Personalized Checklist